title: Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report.
abstract: The safety and efficacy of micafungin were evaluated in a Japanese post-marketing survey involving 1,142 patients with deep mycosis caused by Candida or Aspergillus. The overall clinical response was 83.0%, and the respective responses for patients with candidiasis or aspergillosis were 86.3 and 70.8%. With regard to drug reactions, 562 adverse reactions were observed in 28.5% of patients. Among the 83 serious adverse drug reactions reported by 53 patients, a causal relationship with micafungin was assessed as definite or probable for 6 reactions in 5 patients. Age and baseline hepatic and renal function status did not affect the incidence of adverse reactions, although incidence increased significantly in proportion to the severity of mycosis and daily dose (p < 0.01). In multiple logistic regression analysis, neither baseline hepatic impairment nor increased daily dose of micafungin affected the incidence of hepatobiliary disorders, however, the severity of mycosis was found to correlate significantly with hepatobiliary disorders (p = 0.031). Taken together, our post-marketing findings show that micafungin is effective against deep mycosis caused by Candida or Aspergillus in patients across a range of backgrounds.
authors: Post-Marketing Medical Research, Astellas Pharma Inc., 3-17-1 Hasune, Itabashi-ku, Tokyo 174-8612, Japan. tomoko.hanadate@jp.astellas.com
authors: Tomoko
authors: T
authors: Hanadate
authors: Masahiro
authors: M
authors: Wakasugi
authors: Keizo
authors: K
authors: Sogabe
authors: Toshimitsu
authors: T
authors: Kobayashi
authors: Hisanori
authors: H
authors: Horita
authors: Ikuo
authors: I
authors: Kawamura
authors: Yasuhiro
authors: Y
authors: Hori
authors: Keita
authors: K
authors: Matsui
authors: Yo
authors: Y
authors: Hoshino
authors: Masahiro
authors: M
authors: Sou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001228:Aspergillosis / Q000188:drug therapy*; D001230:Aspergillus / Q000302:isolation & purification; D002175:Candida / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy*; D054714:Echinocandins / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan; D055666:Lipopeptides / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D000077551:Micafungin; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin